Literature DB >> 16399699

L-tyrosine contributes to (+)-3,4-methylenedioxymethamphetamine-induced serotonin depletions.

Joseph M Breier1, Michael G Bankson, Bryan K Yamamoto.   

Abstract

The specific mechanisms underlying (+)-3,4-methylenedioxymethamphetamine (MDMA)-induced damage to 5-HT terminals are unknown. Despite the hypothesized role for dopamine (DA) and DA-derived free radicals in mediating this damage, it remains unclear why MDMA produces long-term depletions of 5-HT in brain regions that are sparsely innervated by DA neurons. We hypothesized that the precursor to DA biosynthesis, tyrosine, mediates MDMA-induced 5-HT depletions. Extracellular tyrosine concentrations increased fivefold in striatum and 2.5-fold in hippocampus during the administration of neurotoxic doses of MDMA. In vitro results show that L-tyrosine can be hydroxylated nonenzymatically to the DA precursor l-3,4-dihydroxyphenylalanine (DOPA) under pro-oxidant conditions. The local infusion of L-tyrosine into the striatum or hippocampus during MDMA administration potentiated the acute increase in extracellular DA and the long-term depletion of 5-HT after MDMA. Coinfusion of the aromatic amino acid decarboxylase (AADC) inhibitor m-hydroxybenzylhydrazine attenuated these effects in hippocampus and decreased basal extracellular DA in the striatum. In contrast, the reverse dialysis of the tyrosine hydroxylase inhibitor alpha-methyl-p-tyrosine into the hippocampus did not affect MDMA-induced increases in extracellular DA or the long-term depletion in 5-HT. These results show that MDMA increases the concentration of tyrosine in the brain to cause a long-term depletion of 5-HT via the nonenzymatic, tyrosine hydroxylase-independent, hydroxylation of tyrosine to DOPA and subsequently to DA via AADC. Overall, the findings suggest that MDMA depletes 5-HT by increasing tyrosine and its eventual conversion to DA within 5-HT terminals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16399699      PMCID: PMC6674330          DOI: 10.1523/JNEUROSCI.3353-05.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  66 in total

1.  Improved method for the measurement of large neutral amino acids in biological matrices.

Authors:  R Bongiovanni; B K Yamamoto; G E Jaskiw
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-04-25

2.  Investigation of the prejunctional alpha2-adrenoceptor mediated actions of MDMA in rat atrium and vas deferens.

Authors:  A Lavelle; V Honner; J R Docherty
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

3.  3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose.

Authors:  B Esteban; E O'Shea; J Camarero; V Sanchez; A R Green; M I Colado
Journal:  Psychopharmacology (Berl)       Date:  2001-03       Impact factor: 4.530

4.  Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate.

Authors:  W L Nixdorf; K B Burrows; G A Gudelsky; B K Yamamoto
Journal:  J Neurochem       Date:  2001-04       Impact factor: 5.372

5.  Newly synthesized dopamine in the nucleus accumbens is regulated by beta-adrenergic, but not alpha-adrenergic, receptors.

Authors:  T Tuinstra; A R Cools
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

6.  Effect of depleting vesicular and cytoplasmic dopamine on methylenedioxymethamphetamine neurotoxicity.

Authors:  Jie Yuan; Branden J Cord; Una D McCann; Brian T Callahan; George A Ricaurte
Journal:  J Neurochem       Date:  2002-03       Impact factor: 5.372

7.  Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine.

Authors:  M Shankaran; B K Yamamoto; G A Gudelsky
Journal:  Eur J Pharmacol       Date:  1999-12-03       Impact factor: 4.432

8.  Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT.

Authors:  M Shankaran; B K Yamamoto; G A Gudelsky
Journal:  Synapse       Date:  2001-04       Impact factor: 2.562

9.  An antisense oligonucleotide targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA.

Authors:  Erin M Falk; Valerie J Cook; David E Nichols; Jon E Sprague
Journal:  Pharmacol Biochem Behav       Date:  2002-06       Impact factor: 3.533

10.  3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.

Authors:  Vincent Setola; Sandra J Hufeisen; K Jane Grande-Allen; Ivan Vesely; Richard A Glennon; Bruce Blough; Richard B Rothman; Bryan L Roth
Journal:  Mol Pharmacol       Date:  2003-06       Impact factor: 4.436

View more
  20 in total

Review 1.  Causes and consequences of methamphetamine and MDMA toxicity.

Authors:  Maria S Quinton; Bryan K Yamamoto
Journal:  AAPS J       Date:  2006-05-12       Impact factor: 4.009

Review 2.  Amphetamine toxicities: classical and emerging mechanisms.

Authors:  Bryan K Yamamoto; Anna Moszczynska; Gary A Gudelsky
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

3.  Ceftriaxone attenuates ethanol drinking and restores extracellular glutamate concentration through normalization of GLT-1 in nucleus accumbens of male alcohol-preferring rats.

Authors:  Sujan C Das; Bryan K Yamamoto; Alexandar M Hristov; Youssef Sari
Journal:  Neuropharmacology       Date:  2015-05-19       Impact factor: 5.250

4.  MDMA-induced neurotoxicity: long-term effects on 5-HT biosynthesis and the influence of ambient temperature.

Authors:  Esther O'Shea; Laura Orio; Isabel Escobedo; Veronica Sanchez; Jorge Camarero; Alfred Richard Green; Maria Isabel Colado
Journal:  Br J Pharmacol       Date:  2006-06-12       Impact factor: 8.739

Review 5.  Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans.

Authors:  A R Green; M V King; S E Shortall; K C F Fone
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

6.  Chronic administration of THC prevents the behavioral effects of intermittent adolescent MDMA administration and attenuates MDMA-induced hyperthermia and neurotoxicity in rats.

Authors:  Erica Y Shen; Syed F Ali; Jerrold S Meyer
Journal:  Neuropharmacology       Date:  2011-07-13       Impact factor: 5.250

7.  Direct and decarboxylation-dependent effects of neurotransmitter precursors on firing of isolated monoaminergic neurons.

Authors:  Varvara E Dyakonova; Ilya A Chistopolsky; Taisia L Dyakonova; Dmitry D Vorontsov; Dmitri A Sakharov
Journal:  J Comp Physiol A Neuroethol Sens Neural Behav Physiol       Date:  2009-03-10       Impact factor: 1.836

8.  Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines.

Authors:  T Montgomery; C Buon; S Eibauer; P J Guiry; A K Keenan; G J McBean
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

Review 9.  The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse.

Authors:  Bryan K Yamamoto; Jamie Raudensky
Journal:  J Neuroimmune Pharmacol       Date:  2008-08-15       Impact factor: 4.147

10.  The relationship between core body temperature and 3,4-methylenedioxymethamphetamine metabolism in rats: implications for neurotoxicity.

Authors:  Beatriz Goni-Allo; Brian O Mathúna; Mireia Segura; Elena Puerta; Berta Lasheras; Rafael de la Torre; Norberto Aguirre
Journal:  Psychopharmacology (Berl)       Date:  2007-12-12       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.